Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: Study
Bharat Biotech’s indigenously developed Covid-19 vaccine Covaxin was overall found to have “much lower” AEFI (adverse effects following immunisation) rates in adolescents with a favourable short-term safety profile as compared to those reported with mRNA vaccines but adolescent females and those with a history of allergy were at a 1.6 times and three times increased risk of AEFI after taking Covaxin.
|
||||
|
||||
You Might Like💡 newsR Knowledge: Other News MentionsCOVID-19 Contagious disease caused by SARS-CoV-2'How can anyone trust you? - Sunak challenged over COVID parties by man who lost his motherRishi Sunak has been challenged over COVID parties in Downing Street while out on the campaign trail for the general election.Sky News Boris Johnson's work style during COVID 'very frustrating' and 'dysfunctional' - head of civil serviceThe UK's top civil servant has told the COVID inquiry he found Boris Johnson's style of working "very frustrating" and "dysfunctional".Sky News Rahul Gandhi's Hilarious Jibe At PM Modi Over 'I Am Not Born Biologically' Remark Credit: Oneindia Duration: 03:09Published How the EU is plotting a course out of COVID debt to greener future Credit: euronews (in English) Duration: 00:56Published From crisis to cooperation: how the EU handled the troubled 2019-2024 era Credit: euronews (in English) Duration: 08:00Published Messenger RNA RNA that is read by the ribosome to produce a proteinMelanoma patient praises new 'game-changer' jab Credit: ODN Duration: 00:50Published Related news from verified sources
|